The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics

Seminars in Cell and Developmental Biology

Volumn 21, Issue 9, 2010, Pages 944-950

  Amin, Dhara N ^a   Campbell, Marcia R ^a   Moasser, Mark M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ErbB3; HER3; Resistance; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; DISEASE SEVERITY; DRUG EFFICACY; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; ONCOGENE; OVARY CANCER; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 78449303095     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2010.08.007     Document Type: Review

References (92)

1. Zhang X., Gureasko J., Shen K., Cole P.A., Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137-1149.
2. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16:5276-5287.
3. Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996, 15:2452-2467.
4. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., Carraway K.L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 1994, 91:8132-8136.
5. Sierke S.L., Cheng K., Kim H.H., Koland J.G. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J 1997, 322:757-763.
6. Jura N., Shan Y., Shaw D.E., Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Nat Acad Sci USA 2009, 106:21608-21613.
7. Soltoff S.P., Carraway K.L., Prigent S.A., Gullick W.G., Cantley L.C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994, 14:3550-3558.
8. Prigent S.A., Gullick W.J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994, 13:2831-2841.
9. Fedi P., Pierce J.H., Di Fiore P.P., Kraus M.H. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 1994, 14:492-500.
10. Kainulainen V., Sundvall M., MA{currency sign}A{currency sign}ttA{currency sign} J.A., Santiestevan E., Klagsbrun M., Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000, 275:8641-8649.
11. Berger M.B., Mendrola J.M., Lemmon M.A. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface 2004, p. 332-6.
12. Kani K., Warren C.M., Kaddis C.S., Loo J.A., Landgraf R. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin 2005, p. 8238-47.
13. Koutras A.K., Fountzilas G., Kalogeras K.T., Starakis I., Iconomou G., Kalofonos H.P. The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol 2010, 74:73-78.
14. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200:290-297.
15. Barnes N.L., Khavari S., Boland G.P., Cramer A., Knox W.F., Bundred N.J. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005, 11:2163-2168.
16. Jones R.B., Gordus A., Krall J.A., MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006, 439:168-174.
17. Schulze W.X., Deng L., Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005, 1:2005.0008.
18. Bellacosa A., Kumar C.C., Di Cristofano A., Testa J.R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005, 94:29-86.
19. Bhaskar P.T., Hay N. The two TORCs and Akt. Dev Cell 2007, 12:487-502.
20. Huang J., Manning B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009, 37:217-222.
21. Zhang K., Sun J., Liu N., Wen D., Chang D., Thomason A., et al. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 1996, 271:3884-3890.
22. Jeong E.G., Soung Y.H., Lee J.W., Lee S.H., Nam S.W., Lee J.Y., et al. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer 2006, 119:2986-2987.
23. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005, 65:7591-7595.
24. Sassen A., Rochon J., Wild P., Hartmann A., Hofstaedter F., Schwarz S., et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008, 10:13.
25. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938.
26. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887.
27. Naidu R., Yadav M., Nair S., Kutty M.K. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998, 78:1385-1390.
28. Tokunaga E., Kimura Y., Oki E., Ueda N., Futatsugi M., Mashino K., et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 2006, 118:284-289.
29. Zhou X., Tan M., Stone Hawthorne V., Klos K.S., Lan K.H., Yang Y., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10:6779-6788.
30. Bieche I., Onody P., Tozlu S., Driouch K., Vidaud M., Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003, 106:758-765.
31. Karamouzis M.V., Badra F.A., Papavassiliou A.G. Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 2007, 39:851-856.
32. Pawlowski V., Revillion F., Hebbar M., Hornez L., Peyrat J.P. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000, 6:4217-4225.
33. Travis A., Pinder S.E., Robertson J.F., Bell J.A., Wencyk P., Gullick W.J., et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 1996, 74:229-233.
34. Reschke M., Mihic-Probst D., van der Horst E.H., Knyazev P., Wild P.J., Hutterer M., et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 2008, 14:5188-5197.
35. Buac K., Xu M., Cronin J., Weeraratna A.T., Hewitt S.M., Pavan W.J. NRG1/ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation. Pigment Cell Melanoma Res 2009, 22:773-784.
36. Kluger H.M., DiVito K., Berger A.J., Halaban R., Ariyan S., Camp R.L., et al. Her2/neu is not a commonly expressed therapeutic target in melanoma-a large cohort tissue microarray study. Melanoma Res 2004, 14:207-210.
37. Ueno Y., Sakurai H., Tsunoda S., Choo M.K., Matsuo M., Koizumi K., et al. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 2008, 123:340-347.
38. Prickett T.D., Agrawal N.S., Wei X., Yates K.E., Lin J.C., Wunderlich J.R., et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009, 41:1127-1132.
39. Soler M., Mancini F., Meca-Cortes O., Sanchez-Cid L., Rubio N., Lopez-Fernandez S., et al. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer 2009, 125:2565-2575.
40. Ciardiello F., Kim N., Saeki T., Dono R., Persico M.G., Plowman G.D., et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA 1991, 88:7792-7796.
41. Rajkumar T., Gooden C.S., Lemoine N.R., Gullick W.J., Goden C.S. Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. J Pathol 1993, 170:271-278.
42. Maurer C.A., Friess H., Kretschmann B., Zimmermann A., Stauffer A., Baer H.U., et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998, 29:771-777.
43. Kountourakis P., Pavlakis K., Psyrri A., Rontogianni D., Xiros N., Patsouris E., et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006, 6:46.
44. Kapitanovic S., Radosevic S., Slade N., Kapitanovic M., Andelinovic S., Ferencic Z., et al. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 2000, 126:205-211.
45. Lee D., Yu M., Lee E., Kim H., Yang Y., Kim K., et al. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest 2009, 119:2702-2713.
46. Fujimoto N., Wislez M., Zhang J., Iwanaga K., Dackor J., Hanna A.E., et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005, 65:11478-11485.
47. Reinmuth N., Jauch A., Xu E.C., Muley T., Granzow M., Hoffmann H., et al. Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer 2008, 62:193-201.
48. Rickman O.B., Vohra P.K., Sanyal B., Vrana J.A., Aubry M.C., Wigle D.A., et al. Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res 2009, 15:3315-3324.
49. Sun M., Behrens C., Feng L., Ozburn N., Tang X., Yin G., et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 2009, 15:4829-4837.
50. Yi E.S., Harclerode D., Gondo M., Stephenson M., Brown R.W., Younes M., et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 1997, 10:142-148.
51. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
52. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
53. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005, 102:3788-3793.
54. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
55. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
56. Li L., Zhong Y.P., Zhang W., Zhang J.Q., Yao Z.Q. Relationship of expression of C-erbB2, C-erbB3, and C-erbB4 with ovarian carcinoma. Ai Zheng 2004, 23:568-572.
57. Gilmour L.M., Macleod K.G., McCaig A., Sewell J.M., Gullick W.J., Smyth J.F., et al. Neuregulin expression, function, and signaling in human ovarian cancer cells. Clin Cancer Res 2002, 8:3933-3942.
58. Rajkumar T., Stamp G.W., Hughes C.M., Gullick W.J. c-erbB3 protein expression in ovarian cancer. Clin Mol Pathol 1996, 49:M199-M202.
59. Leng J., Lang J., Shen K., Guo L. Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chin Med Sci J 1997, 12:67-70.
60. Simpson B.J., Phillips H.A., Lessells A.M., Langdon S.P., Miller W.R. c-erbB growth-factor-receptor proteins in ovarian tumours. Int J Cancer 1995, 64:202-226.
61. Simpson B.J., Weatherill J., Miller E.P., Lessells A.M., Langdon S.P., Miller W.R. c-erbB-3 protein expression in ovarian tumours. Br J Cancer 1995, 71:758-762.
62. Tanner B., Hasenclever D., Stern K., Schormann W., Bezler M., Hermes M., et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006, 24:4317-4323.
63. Sheng Q., Liu X., Fleming E., Yuan K., Piao H., Chen J., et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010, 17:298-310.
64. Addo-Yobo S.O., Straessle J., Anwar A., Donson A.M., Kleinschmidt-DeMasters B.K., Foreman N.K. Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma. J Neuropathol Exp Neurol 2006, 65:769-775.
65. Ritch P.S., Carroll S.L., Sontheimer H. Neuregulin-1 enhances survival of human astrocytic glioma cells. Glia 2005, 51:217-228.
66. Donson A.M., Erwin N.S., Kleinschmidt-DeMasters B.K., Madden J.R., Addo-Yobo S.O., Foreman N.K. Unique molecular characteristics of radiation-induced glioblastoma. J Neuropathol Exp Neurol 2007, 66:740-749.
67. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
68. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999, 26:78-83.
69. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
70. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
71. Cai Z., Zhang G., Zhou Z., Bembas K., Drebin J.A., Greene M.I., et al. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene 2008, 27:3870-3874.
72. Yao E., Zhou W., Lee-Hoeflich S.T., Truong T., Haverty P.M., Eastham-Anderson J., et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 2009, 15:4147-4156.
73. Fuino L., Bali P., Wittmann S., Donapaty S., Guo F., Yamaguchi H., et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003, 2:971-984.
74. Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007, 99:628-638.
75. Weiner D.B., Kokai Y., Wada T., Cohen J.A., Williams W.V., Greene M.I. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene 1989, 4:1175-1183.
76. Blackwell K.L., Pegram M.D., Tan-Chiu E., Schwartzberg L.S., Arbushites M.C., Maltzman J.D., et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009, 20:1026-1031.
77. Burstein H.J., Storniolo A.M., Franco S., Forster J., Stein S., Rubin S., et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008, 19:1068-1074.
78. Burstein H.J., Sun Y., Tan A.R., Dirix L., Vermette J.J., Powell C., et al. Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. San Antonio Breast Cancer Symposium 2008, Abstr #37.
79. Kaufman B., Trudeau M., Awada A., Blackwell K., Bachelot T., Salazar V., et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009, 10:581-588.
80. Gomez H.L., Chavez M.A., Doval D.C., Franco S., Arbushites M., Berger M.S., et al. Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer. Proc Am Soc Clin Oncol 2007, 25:#10562.
81. Iwata H., Toi M., Fujiwara Y., Ito Y., Fujii H., Nakamura S., et al. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium 2006, #1091.
82. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
83. Amin D.N., Sergina N., Ahuja D., McMahon M., Blair J.A., Wang D., et al. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2010, 2(16):ra7.
84. Folgiero V., Bachelder R.E., Bon G., Sacchi A., Falcioni R., Mercurio A.M. The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function. Cancer Res 2007, 67:1645-1652.
85. Cao Z., Wu X., Yen L., Sweeney C., Carraway K.L. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Mol Cell Biol 2007, 27:2180-2188.
86. Yen L., Cao Z., Wu X., Ingalla E.R., Baron C., Young L.J., et al. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res 2006, 66:11279-11286.
87. Laederich M.B., Funes-Duran M., Yen L., Ingalla E., Wu X., Carraway K.L., et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004, 279:47050-47056.
88. Miller J.K., Shattuck D.L., Ingalla E.Q., Yen L., Borowsky A.D., Young L.J., et al. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 2008, 68:8286-8294.
89. Funes M., Miller J.K., Lai C., Carraway K.L., Sweeney C. The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J Biol Chem 2006, 281:19310-19319.
90. Iorio M.V., Casalini P., Piovan C., Di Leva G., Merlo A., Triulzi T., et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009, 69:2195-2200.
91. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borras A.M., Gale C.M., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006, 116:2695-2706.
92. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.